- Home
- STUB vs ABSI Comparison
STUB vs ABSI Comparison
Compare STUB & ABSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | STUB | ABSI |
|---|---|---|
| Founded | 2000 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 1.4B |
| IPO Year | 2025 | 2021 |
Fundamental Metrics
Financial Performance| Metric | STUB | ABSI |
|---|---|---|
| Price | $5.87 | $9.13 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 11 |
| Target Price | $10.54 | ★ $14.90 |
| AVG Volume (30 Days) | ★ 4.5M | 3.6M |
| Earning Date | 11-10-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 10.64 |
| EPS | ★ 0.06 | N/A |
| Revenue | ★ $1,745,188,000.00 | $4,534,000.00 |
| Revenue This Year | $15.84 | $39.03 |
| Revenue Next Year | $9.82 | $310.91 |
| P/E Ratio | $101.50 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.22 | $2.24 |
| 52 Week High | $20.54 | $12.06 |
Technical Indicators
Market Signals| Indicator | STUB | ABSI |
|---|---|---|
| Relative Strength Index (RSI) | 47.68 | 48.08 |
| Support Level | $5.65 | $8.15 |
| Resistance Level | $6.38 | $11.73 |
| Average True Range (ATR) | 0.27 | 0.86 |
| MACD | 0.07 | -0.06 |
| Stochastic Oscillator | 40.51 | 26.66 |
Price Performance
Historical ComparisonAbout STUB StubHub Holdings Inc.
Stubhub Holdings Inc operates a ticketing marketplace for live events where fans can buy tickets from sellers of all types through its StubHub and viagogo websites and mobile applications. The company generates majority of its revenue from United States.
About ABSI Absci Corporation
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process. Its lead product candidate, ABS-201, is an anti-prolactin receptor (PRLR) antibody engineered with an extended half-life to support a patient-friendly dosing interval.